Gain Therapeutics (GANX) director granted 25,000 stock options at $1.68
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Gain Therapeutics director Khalid Islam reported a grant of stock options for 25,000 shares of common stock on July 15, 2026. The options carry a $1.6800 exercise price, expire on July 15, 2036, and vest in 12 equal monthly installments starting July 24, 2026, contingent on his continuous service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Islam Khalid
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 25,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 25,000 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Options Granted: 25000.0000 options
Exercise Price: $1.6800 per share
Underlying Shares: 25000.0000 shares
+4 more
7 metrics
Options Granted
25000.0000 options
Stock option grant to director on 2026-07-15
Exercise Price
$1.6800 per share
Conversion or exercise price of the stock options
Underlying Shares
25000.0000 shares
Common shares underlying the stock options granted
Vesting Installments
12 monthly installments
Options vest in 12 equal monthly installments starting 2026-07-24
Vesting Start Date
2026-07-24
Commencement of monthly vesting schedule, subject to continuous service
Expiration Date
2036-07-15
Expiration date of the granted stock options
Post-Transaction Options Held
25000.0000 options
Total options held directly by Khalid Islam after the grant
Key Terms
Stock Option (right to buy), exercise price, vesting, expiration date
4 terms
Stock Option (right to buy) financial
"Security reported as "Stock Option (right to buy)" for the director"
exercise price financial
"Conversion or exercise price of $1.6800 per share on the option grant"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The option vests in 12 equal monthly installments commencing on July 24, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"Reported expiration date of the options is July 15, 2036"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did GANX director Khalid Islam report?
Khalid Islam reported a grant of stock options for 25,000 shares of Gain Therapeutics common stock. These options were awarded on July 15, 2026 as equity compensation rather than an open-market purchase or sale.
How many Gain Therapeutics (GANX) options were granted and at what price?
Khalid Islam received 25,000 stock options with a $1.6800 exercise price per share. Each option allows the purchase of one share of Gain Therapeutics common stock at that price if and when the option is vested and exercised.
When do the GANX stock options granted to Khalid Islam vest?
The options vest in 12 equal monthly installments starting on July 24, 2026. Vesting is conditioned on Khalid Islam’s continuous service to Gain Therapeutics through each applicable monthly vesting date.
What is the expiration date of Khalid Islam’s GANX stock options?
The granted options expire on July 15, 2036. After that expiration date, any unexercised options will lapse and can no longer be used to acquire Gain Therapeutics common stock at the $1.6800 exercise price.
Did the GANX Form 4 show any stock sales or open-market buys?
No. The Form 4 reports only a grant of stock options, not any open-market purchases or sales of Gain Therapeutics common shares. The transaction is classified as a derivative award acquisition, not a buy or sell.
How many Gain Therapeutics options does Khalid Islam hold after this grant?
Following the reported transaction, Khalid Islam holds 25,000 stock options as reflected in the Form 4. These options are subject to the disclosed vesting schedule and expiration date and are held as a direct ownership position.